Health Care & Life Sciences » Biotechnology | BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
12,591.80
20,711.30
33,485.40
49,018.20
59,307.80
80,883.60
Total Accounts Receivable
5,260.10
3,640.20
3,464.80
4,305.50
4,655.10
16,518.70
Other Current Assets
421.50
227.80
400.70
624.30
623.50
646.70
Total Current Assets
18,273.50
24,579.20
37,350.90
53,948.10
64,586.40
98,049
Total Investments and Advances
-
1,250.00
3,596.50
3,771.40
5,746.00
1,099.80
Intangible Assets
216.00
295.00
275.20
258.40
398.00
444.50
Other Assets
3,350.00
3,840.80
3,869.40
3,428.40
2,526.30
184.90
Total Assets
23,252.20
31,026.80
45,698.10
64,696.30
74,996.40
100,092
Accounts Payable
409.60
309.20
372.40
505.10
568.00
Income Tax Payable
-
-
-
-
68.70
Other Current Liabilities
371.90
362.00
466.20
1,491.50
1,502.10
Total Current Liabilities
781.50
671.20
838.50
1,996.60
2,138.80
Deferred Taxes
1,412.80
1,061.90
606.10
3,290.10
1,739.70
Other Liabilities
138.30
98.80
49.40
6,417.70
5,340.70
Total Liabilities
919.80
770.00
887.90
8,414.30
7,479.60
Common Equity (Total)
22,332.40
30,256.90
44,810.20
56,281.90
67,516.80
Total Shareholders' Equity
22,332.40
30,256.90
44,810.20
56,281.90
67,516.80
Total Equity
22,332.40
30,256.90
44,810.20
56,281.90
67,516.80
Liabilities & Shareholders' Equity
23,252.20
31,026.80
45,698.10
64,696.30
74,996.40

About BioSpecifics Technologies

View Profile
Address
35 Wilbur Street
Lynbrook New York 11563
United States
Employees -
Website http://www.biospecifics.com
Updated 07/08/2019
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren's contracture. The company was founded in 1990 and is headquartered in Lynbrook, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.